A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Merck Sharp & Dohme LLC
Pfizer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Seagen Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
OHSU Knight Cancer Institute
Eli Lilly and Company
Jiangsu HengRui Medicine Co., Ltd.
M.D. Anderson Cancer Center
Inspirna, Inc.
EpicentRx, Inc.
Huabo Biopharm Co., Ltd.
Albert Einstein College of Medicine
Agenus Inc.
Augusta University
Dana-Farber Cancer Institute
GOG Foundation
GOG Foundation
University of Arizona
University of Arizona
Washington University School of Medicine
GOG Foundation
GOG Foundation
GOG Foundation
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
SCRI Development Innovations, LLC
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company